Global

‡ In these countries please contact our distributor

Abstract #15

Smith & Nephew logo
Iodosorb* 0.9% Cadexomer Iodine

 

 

Ishibashi, Y
J. clin. Therap. Med, 6(4) 785-816, 1990 (Japan)

 

 

Clinical Evaluation of NI-009 (Cadexomer Iodine) on Various Cutaneous Ulcers - Comparative Study with Debrisan.

 

Clinical Paper Abstract

A randomized group comparative study was conducted to study the utility of cadexomer iodine on various cutaneous ulcers using Debrisan as a control at 38 institutes.

 

  1. Of 145 patients enrolled in the study, 145 cases (cadexomer iodine:73 and Debrisan: 72) were analysed
  2. Concerning the improvement rating, the cadexomer iodine group was found to be superior to the Debrisan group in the ‘volume of pus' in the total cases, and in the ‘size of the ulcer', ‘volume of exudate', ‘volume of pus', and ‘formation of granulation' in bed sores
  3. The reduction rates of ulcer size (more than 50%) were 57.7% of the cadexomer iodine group and 27.3% of the Debrisa n group for bed sores, namely the cadexomer iodine group was superior to the Debrisan group
  4. For bed sores, the cadexomer iodine group was superior to the Debrisan group at all evaluation dates in the overall improvement rating
  5. With respect to the bacteriological findings, the cadexomer iodine group was superior to the Debrisan group in the reappearance rate in the total cases and bed sores and for disappearance rate in Ps. aeruginosa
  6. The overall effective rates (“effective” and more) were 74.6% of the total case, 69.2% of bed sores, and 78.8% of the other ulcers in N group, and 68.9%, 36.4% and 87.2% in the Debrisan group, respectively. Namely, the cadexomer iodine group was superior to the Debrisan group in bed sores
  7. Side effects were noted in 2 of the cadexomer iodine group and 3 in the Debrisan group. The conditions were pain, irritation, itching and redness in the cadexomer iodine group pain in 3 of the Debrisan group

     

    These effects disappeared during the treatment course or after discontinuations of dr ug administration. Furthermore, no abnormal laboratory findings were noted in the two groups.

     

  8. The overall safety rates assessed as ‘no problem' were 97.3% of the cadexomer iodine group and 95.8% of the Debrisan group
  9. The utility rates assessed as ‘useful ' and more were 72.1% of the total case, 69.2% of bed sores, and 74.3% of other ulcers in the N group, and 68.3%, 40.9% and 82.9%, respectively, in the D group. Namely, the N group was superior to the D group in bed sores

 

These results suggest that cadexomer iodine is a useful drug, equivalent to Debrisan in the treatment of various cutaneous ulcers, especially for bed sores in which bacteriological infections are often observed.

 

Slough Removal Antibacterial Efficacy Sustained Antibacterial effect Exudate Management Effective Wound Healing Odour Patient Comfort Cost/Time Savings Sensitivity
X X